Clinical Judgment Versus Biomarker Prostate Cancer Gene 3: Which Is Best When Determining the Need for Repeat Prostate Biopsy?
Authors:
- Bertrand TombalBTBertrand Tombal
- Gerald L. AndrioleGAGerald L. Andriole
- Alexandre de la TailleATAlexandre de la Taille
- Paolo GonteroPGPaolo Gontero
- Alexander HaeseAHAlexander Haese
- Mesut RemziMRMesut Remzi
- Mark SpeakmanMSMark Speakman
- Louis SmetsLSLouis Smets
- Herman StoevelaarHSHerman Stoevelaar
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Gen-Probe, Inc
This publication has 15 references indexed in Scilit:
- A comparative performance analysis of total prostate‐specific antigen, percentage free prostate‐specific antigen, prostate‐specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsyBJU International, 2011
- Repeat Prostate Biopsy and the Incremental Risk of Clinically Insignificant Prostate CancerUrology, 2011
- Prostate Cancer Antigen 3 Score Accurately Predicts Tumour Volume and Might Help in Selecting Prostate Cancer Patients for Active SurveillanceEuropean Urology, 2011
- Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer StagingEuropean Urology, 2011
- Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate samplingBJU International, 2010
- Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat BiopsyEuropean Urology, 2008
- EAU Guidelines on Prostate CancerEuropean Urology, 2008
- Prostate Cancer Testing following a Negative Prostate Biopsy: Over Testing the ElderlyJournal of General Internal Medicine, 2007
- PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat BiopsyUrology, 2007
- Screening for prostate cancerEuropean Journal of Cancer, 2005